Endocarditis diagnostic study of choice
Jump to navigation
Jump to search
|
Endocarditis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease |
|
Case Studies |
|
Endocarditis diagnostic study of choice On the Web |
|
to Hospitals Treating Endocarditis diagnostic study of choice |
|
Risk calculators and risk factors for Endocarditis diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: : Anum Ijaz M.B.B.S., M.D.[2]
Overview
The diagnosis of infective endocarditis (IE) integrates clinical, microbiologic, imaging, and pathologic/surgical data rather than relying on any single test. The diagnostic framework of choice is the 2023 Duke–ISCVID (International Society for Cardiovascular Infectious Diseases) criteria, the current update to the 1994/2000 Duke framework, incorporating molecular microbiology, cardiac CT, and 18F-FDG PET/CT.[1] External validation shows improved sensitivity (~84% vs ~75%) over the 2000 modified Duke criteria without significant loss of specificity in the derivation cohort.[2] Blood cultures are the single most important diagnostic test and echocardiography is the primary imaging modality; both feed directly into the criteria.[3]
Diagnostic Study of Choice
Study of Choice
IE is diagnosed clinically using the 2023 Duke–ISCVID criteria, which combine microbiologic, imaging, clinical, and surgical/pathologic findings into major and minor criteria. No single test is diagnostic in isolation. Definite pathologic IE — organism identified, or active endocarditis confirmed histologically, in a vegetation, cardiac tissue, explanted prosthetic material, ascending aortic graft, endovascular CIED, or arterial embolus — remains the reference standard.[3] The concurrently published 2023 ESC criteria are similar but not identical (see below), and no consensus exists on which to prefer.[3][2]
2023 Duke–ISCVID Criteria
Major Criteria
- Microbiologic
- Positive blood cultures: typical IE organisms from ≥2 separate blood culture sets; OR organisms that occasionally/rarely cause IE from ≥3 separate sets
- Positive laboratory tests: PCR/nucleic-acid detection of Coxiella burnetii, Bartonella spp., or Tropheryma whipplei from blood; OR C. burnetii antiphase I IgG titer >1:800 or a single positive culture; OR Bartonella henselae/B. quintana indirect immunofluorescence IgG ≥1:800
- Imaging
- Echocardiography or cardiac CT: vegetation, valvular perforation/aneurysm, abscess, pseudoaneurysm, or intracardiac fistula; OR significant new valvular regurgitation vs prior imaging; OR new partial dehiscence of a prosthetic valve
- 18F-FDG PET/CT: abnormal metabolic activity at a native or prosthetic valve, ascending aortic graft (with concomitant valve involvement), intracardiac device leads, or other prosthetic material (performed ≥3 months after surgical prosthetic valve implantation)
- Surgical (new in 2023): IE documented by direct intraoperative inspection, even without subsequent histologic or microbiologic confirmation
Minor Criteria
- Predisposition: prior IE, prosthetic valve or previous valve repair, congenital heart disease, more than mild regurgitation or stenosis of any etiology, endovascular CIED, hypertrophic obstructive cardiomyopathy, or injection drug use
- Fever: temperature >38.0°C (100.4°F)
- Vascular phenomena: major arterial emboli, septic pulmonary infarcts, cerebral or splenic abscess, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, Janeway lesions
- Immunologic phenomena: positive rheumatoid factor, Osler's nodes, Roth spots, or immune-complex mediated glomerulonephritis (redefined to include unexplained acute kidney injury with hematuria, proteinuria, casts, or serologic perturbations)
- Imaging (minor): abnormal metabolic activity detected by 18F-FDG PET/CT within 3 months (<3 months) of implantation of a prosthetic valve, ascending aortic graft, intracardiac device leads, or other prosthetic material (distinct from the major imaging criterion, which requires imaging ≥3 months after implantation)
- Physical examination (new): new valvular regurgitation on auscultation when echocardiography is unavailable
- Microbiologic evidence not meeting a major criterion: positive blood culture (excluding single cultures of common contaminants), or sequencing-based assays consistent with IE
Diagnostic Classification
| Classification | Criteria |
|---|---|
| Definite IE — pathologic | Microorganisms identified in a vegetation, cardiac tissue, explanted prosthetic valve/sewing ring, ascending aortic graft, endovascular CIED, or arterial embolus, in the context of clinical signs of active endocarditis; OR active endocarditis confirmed histologically |
| Definite IE — clinical | 2 major criteria; OR 1 major + 3 minor criteria; OR 5 minor criteria |
| Possible IE | 1 major + 1 minor criterion; OR 3 minor criteria |
| Rejected | Firm alternate diagnosis explaining signs/symptoms; OR lack of recurrence despite antibiotic therapy for <4 days; OR no pathologic evidence of IE at surgery or autopsy after antibiotic therapy for <4 days; OR does not meet criteria for possible IE |
Diagnostic Performance
- 2023 Duke–ISCVID: sensitivity ~84%, specificity 94% in the Amsterdam validation cohort; specificity was substantially lower in other cohorts (60% in a Swiss multicenter study,[4] 46% in a French multicenter cohort[5]), with the reduced specificity mainly attributable to CIED patients.[2]
- 2023 Duke–ESC: sensitivity 73%, specificity 99% in a Swiss streptococcal bacteremia cohort.[6]
- 2000 modified Duke: sensitivity ~75–80% for definite IE; negative predictive value ~90% when neither definite nor possible criteria are met.[7]
- Sensitivity is lower for prosthetic valve IE, CIED IE, right-sided IE, and culture-negative IE.[7]
- The value of fever as a minor criterion has been questioned: a 2025 analysis found fever equally prevalent in IE and non-IE episodes (78% vs 77%), and excluding it improved specificity (49%→80%) without reducing sensitivity.[8]
Key Changes From the 2000 Modified Duke Criteria
| Feature | 2000 Modified Duke | 2023 Duke–ISCVID |
|---|---|---|
| Typical microorganisms | S. aureus, viridans streptococci, S. bovis, HACEK, enterococci | Expanded: adds S. lugdunensis, Enterococcus faecalis (no longer requires community acquisition or absence of a primary focus), all streptococci (except S. pneumoniae and S. pyogenes), Granulicatella/Abiotrophia/Gemella; with intracardiac prosthetic material also CoNS, C. striatum/C. jeikeium, S. marcescens, P. aeruginosa, C. acnes, non-tuberculous mycobacteria (esp. M. chimaera), Candida spp. |
| Blood culture timing/venipuncture | ≥2 cultures >12 h apart, or 3/4 majority ≥1 h apart | Timing and separate-venipuncture requirements removed (separate venipunctures still strongly recommended) |
| Molecular/serologic diagnostics | Not included | PCR for C. burnetii/Bartonella/T. whipplei and serology for C. burnetii/Bartonella qualify as major microbiologic criteria |
| Imaging | Echocardiography only | Cardiac CT and 18F-FDG PET/CT added as major imaging criteria |
| Surgical criterion | Not included | Intraoperative inspection documenting IE is a new major criterion |
| Predisposing conditions | Predisposing heart condition or IDU | Adds prior IE, transcatheter valve implants, endovascular CIED, HOCM |
| Immunologic/vascular phenomena | Glomerulonephritis (undefined), Osler's nodes, Roth spots, rheumatoid factor | Rheumatoid factor retained; glomerulonephritis redefined with specific AKI criteria; cerebral/splenic abscess added to vascular phenomena |
| Physical examination | Not a separate criterion | New valvular regurgitation on auscultation (when echo unavailable) added as minor criterion |
Differences From the 2023 ESC Criteria
- The ESC criteria include SPECT/CT imaging; the Duke–ISCVID criteria do not.[3]
- The Duke–ISCVID criteria contain more detailed microbiologic specifications and include the surgical major criterion; the ESC criteria do not.[3]
- The Duke–ISCVID criteria include a physical-examination minor criterion; the ESC criteria do not.[3]
- On external validation the Duke–ISCVID criteria were similarly sensitive but more specific than the 2023 ESC criteria (specificity 94% vs 82%).[2]
Sequence of Diagnostic Studies
| Suspected infective endocarditis | |||||||||
| ≥2–3 blood culture sets before antibiotics | |||||||||
| Echocardiography: TTE first-line, then TEE if indicated | |||||||||
| If negative but suspicion persists, repeat echo in 5–7 days | |||||||||
| Advanced imaging (cardiac CT, 18F-FDG PET/CT) + molecular/serologic testing; apply 2023 Duke–ISCVID criteria | |||||||||
TEE is indicated for suspected prosthetic-valve or CIED IE, Staphylococcus aureus bacteremia without a clear source, or suspected complications; a negative echocardiogram does not exclude IE.[3][9]
References
- ↑ Fowler VG, Durack DT, Selton-Suty C; et al. (2023). "The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria". Clin Infect Dis. doi:10.1093/cid/ciad271.
- ↑ 2.0 2.1 2.2 2.3 van der Vaart TW, Bossuyt PMM, Durack DT; et al. (2024). "External Validation of the 2023 Duke-International Society for Cardiovascular Infectious Diseases Diagnostic Criteria for Infective Endocarditis". Clin Infect Dis. doi:10.1093/cid/ciae033.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 Dayer MJ, Quintero-Martinez JA, Thornhill MH; et al. (2024). "Recent Insights Into Native Valve Infective Endocarditis: JACC Focus Seminar 4/4". J Am Coll Cardiol. doi:10.1016/j.jacc.2023.12.043.
- ↑ Papadimitriou-Olivgeris M, Monney P, Frank M; et al. (2024). "Evaluation of the 2023 Duke-International Society of Cardiovascular Infectious Diseases Criteria in a Multicenter Cohort of Patients With Suspected Infective Endocarditis". Clin Infect Dis. 78: 949–955. doi:10.1093/cid/ciae039.
- ↑ Goehringer F, Lalloué B, Selton-Suty C; et al. (2024). "Compared Performance of the 2023 Duke-ISCVID, 2000 Modified Duke, and 2015 ESC Criteria for the Diagnosis of Infective Endocarditis in a French Multicenter Prospective Cohort". Clin Infect Dis. 78: 937–948. doi:10.1093/cid/ciae035.
- ↑ Fourré N, Zimmermann V, Senn L; et al. (2024). "Evaluation of the HANDOC Score and the 2023 ISCVID and ESC Duke Clinical Criteria for the Diagnosis of Infective Endocarditis Among Patients With Streptococcal Bacteremia". Clin Infect Dis. 79: 434–442. doi:10.1093/cid/ciae315.
- ↑ 7.0 7.1 Chambers HF, Bayer AS (2020). "Native-Valve Infective Endocarditis". N Engl J Med. doi:10.1056/NEJMcp2000400.
- ↑ Stavropoulou E, Epprecht J, Siedentop B; et al. (2025). "Reassessing the 2023 International Society for Cardiovascular Infectious Diseases Duke Clinical Criteria for Infective Endocarditis: Impact of Excluding Fever and Updating Diagnostic Definitions". Clin Infect Dis. doi:10.1093/cid/ciaf737.
- ↑ Nohria R, Romaine A, Garcia-Sampson G (2026). "Infective Endocarditis: Diagnosis and Treatment". Am Fam Physician.